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Role of an improvement in acid-base status and nutrition in CAPD
patients. Short-term correction of metabolic acidosis in normal and
uremic subjects has been shown to decrease protein degradation, but the
long-term effects of better correction of acidosis on nutrition in ESRF are
unknown. The aim of this study was to assess the possible benefits, in the
nutritional state and morbidity, of improved correction of acidosis in the
first year of treatment with continuous ambulatory peritoneal dialysis
(CAPD). Two hundred consecutive new CAPD patients were randomized,
in a single-blind fashion, to receive a high (HA; lactate 40 mmol/liter) or
low (LA; lactate 35 mmol/liter) alkali dialysate for one year. Calcium
carbonate and sodium bicarbonate were also used to correct acidosis in
the HA group. At one year, the venous serum bicarbonate and arterial pH
were 7.44 0.004 and 27.2 0.3 mmol/liter in the HA group, and 23.0
0.3mmol/liter and 7.4 0.004 in the LA group (P < 0.001). Dialysis dose,
at one year or at the point of leaving the study (HA 8.0 0.1 liters/day vs.
LA 8.5 0.3 liters/day) was not significantly different (P = 0.18). At one
year, the increase in body weight in the HA group (6.1 0.66 kg) was
higher than in the LA group (3.71 0.56 kg, P < 0.05). The increase in
midarm circumference in the HA patients (1.26 0.16 cm) was signifi-
cantly higher than the increase in the LA patients (0.61 0.16 cm, P <
0.05). The increase in triceps skinfold thickness were not significantly
different (HA 2.5 0.41 mm vs. LA 1.24 0.38 mm, P 0.1). Serum
albumin was 37.8 0.4g/dl at one year in the HA group, and 38.2 0.5
g/dl in the LA group (NS). Dietary protein intake at one year (HA 0.9
0.2 g/kglday vs. LA 1.0 0.1 g/kg/day) was not significantly different.
There were fewer hospital admissions in the HA group (1.13 0.16 per
patient per year) compared to the LA group (1.71 0.22 per patient per
year, P < 0.05). The HA patients spent less days in hospital per year than
the LA patients (16.4 1.4 days/year vs. 21.2 1.9 days/year; P < t).05).
It is concluded that better correction of metabolic aeidosis leads to greater
increases in body weight and midarm circumference, hut not triceps
skinfold thickness, in the first year of CAPD. The improvement in
morbidity, in terms of number of admissions and days in hospital per year,
may be associated with the improvement in nutritional state.
Protein malnutrition is a salient feature of chronic renal failure
in humans. A link between metabolic acidosis (MA), renal failure
and protein metabolism was first documented over 75 years ago
when Lyon et al (1931) demonstrated in patients with chronic
renal failure that the blood urea was greater when the patient was
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sustained on an acid rather than alkali generating diet [1]. There
is considerable circumstantial evidence that MA plays a dominant
role in the malnutrition associated with chronic renal failure. In
retrospective studies, better correction of acidosis has been shown
to improve the reduced growth velocity of children with chronic
renal failure [2]. Furthermore, correcting the metabolic acidosis in
patients with non-uremic renal tubular acidosis also improves
growth [31.
Short-term prospective studies in animals and humans have
confirmed these observations, by demonstrating links between
MA and protein metabolism. It has been shown that the induction
of MA in animals with chronic renal failure causes increased
muscle proteolysis [4] that can be reversed with the administration
of sodium bicarbonate. Furthermore, correction of acidosis has
been shown to reduce protein degradation in predialysis patients
[5, 6], and patients on peritoneal dialysis [71 and hemodialysis [8].
The induction of MA in animals increases urea production [4], an
effect reversed by the addition of sodium bicarbonate in both
animals [4] and humans [5, 7—9].
In rats, muscle branch chain amino acid degradation, like
protein degradation, is increased in uraemia acidosis; and, as with
protein degradation, sodium bicarbonate reverses this abnormal-
ity [10]. In patients with chronic renal failure, branch chain amino
acid (BCAA) degradation is accelerated and plasma BCAA levels
are low [111. Finally, there is a strong positive linear correlation
between plasma bicarbonate levels and free valine concentration
in the muscle of hemodialysis patients [12].
Whether this effect, or more particularly the reversal of this
eflèct, has any clinical relevance for patients with chronic renal
failure in the long-term remains unknown. The aim of this study
was to assess the possible benefits, in terms of nutritional state and
morbidity, of improved correction of acidosis in the first year of
continuous ambulatory peritoneal dialysis (CAPD).
METHODS
Permission for the study was granted by the Ethical Com-
mittee of Leicestershire Health Authority. Consent was obtained
from 200 consecutive new CAPD who were randomized, in a
single-blinded fashion, to receive a high alkali (HA; lactate 40
mmol/liter) or low alkali (LA; lactate 35 mmol/liter) dialysatc, and
studied for one year. The HA dialysate contained less calcium
than the LA dialysate (HA, ionized calcium concentration 1.25
mmol/liter vs. LA 1.75 mmol/liter). All patients were treated by
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Table 1. Demographics of etiology of renal failure in the two groups
(at baseline)
Low alkali High alkali
Demographics
Number 100 100
Age years 56.5 1.6 56.0 1.4
Sex male/frmale 67/33 64/36
Ischemic heart disease 27 22
Diabetes mellitus 12 22
Co-morbidity score (max = 7) 0.95 0.11 0.92 0.12
Previously known to unit 66 70
Etiology of renal failure
Unknown 39 32
Diabetic nephropathy 10 18
Inherited disease 8 13
Glomerulonephritis/vasculitis 13 10
Tubulo-interstitial disease 6 9
Myeloma/amyloid 4 7
Renovascular disease/hypertension 6 6
Obstruction/stones 11 5
Other 3 (2 Single kidney,
I Pre-eclampsia)
0
CAPD from the start of renal replacement therapy, and were
recruited between December 1992 and December 1994.
Baseline (time 0) was defined as the day before CAPD catheter
insertion (or the day before the first hemodialysis if appropriate).
Patients were assessed at 0, 1, 3, 6, 9 and 12 months. At the
majority of outpatient appointments, the patients were seen by
one physician (As).
Matching
The two groups were compared in terms of epidemiological
data, causes of renal failure, nutritional state and laboratory
parameters. Data were recorded at baseline or at one month
(indicated in Results).
At baseline, a comorbidity score (maximum = 7)was calculated
for each patient. One 'point' was scored for the presence of
diabetes mellitus (not necessarily the cause of renal failure),
ischemic heart disease, cerebrovascular disease, peripheral vascu-
lar disease, serious malignancy, left ventricular failure and any
other serious comorbid disease.
Laboratory parameters
Serum bicarbonate and albumin were measured at the six
designated time points, using standard laboratory techniques.
Serum cortisol was measured at 1 and 12 months.
Acid-base balance
The target venous bicarbonate level in the HA group was 30
mmol/liter. If this was not achieved with HA dialysate and CaCO3
alone, oral sodium bicarbonate was added at a dose of 0.6 g three
times per day, and increased to a maximum of 1.8 g tds. In the LA
group the venous bicarbonate was ignored, unless a patient was
considered to be symptomatic of acidosis. Arterial pH was mea-
sured from a radial artery sample at one year.
Nutritional assessment
The nutritional state was assessed by experienced renal dieti-
cians. Body weight (without CAPD fluid in the abdomen at
baseline, and thereafter with CAPD fluid in the abdomen if the
patient was still on CAPD) was measured at 0, 1, 6 and 12 months.
Midarm circumference and triceps skinfold thickness were mea-
sured at 1, 6 and 12 months. Serum albumin was measured at all
six assessment points. At one year, a 7-day food record was used
to assess dietary protein intake.
Bone metabolism
A target serum calcium of 2.5 mmol/Iiter was used for both
groups. In order to achieve maximal correction of acidosis in the
HA group and minimal safe correction of acidosis in the LA
group, the method of achieving the target serum phosphate was
different in the two groups.
In the HA group, if possible, CaCO3 alone was used to maintain
serum calcium. From CAPD catheter insertion, patients in this
group received high dose CaCO3 (3 g per day, in the form of
Calcichew Forte® 1 tds). The dose of CaCO3 was increased if
possible to a maximum of 6 g per day to achieve maximal
correction of acidosis. If HA dialysate and 6 g/day of CaCO3 was
not able to maintain the serum calcium at 2.5 mmol/liter or above,
aiphacalcidol at a dose of 0.25 to 1.0 ig once per day was added.
If possible, aluminium hydroxide was not used in the HA group.
In the LA group, no phosphate binder was started at baseline.
If the serum calcium did not reach 2.5 mmol/Iiter by 3 months,
alphacalcidol was added, in the same dose range as the HA group.
If the serum phosphate reached over 2.0 mmol/liter, a small dose
of CaCO3 (0.5 to 1.0 glday; in the form of 1 to 2 Calcichew®
tablets per day) or aluminium hydroxide (950 mg per day, in the
form of 2 Alucaps® per day), or both, were started.
Dialysis dose
The majority of patients were started on four 2-liter exchanges
per day. Dialysis adequacy was assessed using 'conventional'
monitoring of serum urea and creatinine levels. The dialysis dose
was increased if the patient recorded either a serum urea of over
30 mmol/liter or creatinine over 1200 p.mol/liter. The dialysis dose
was decreased if both the serum urea fell to below 15 mmol/liter
and the creatinine to below 500 jimol/liter, in the absence of
clinical evidence of malnutrition. Urea kinetic modeling was
performed at 1, 6 and 12 months, but it should be noted that
treatment was not adjusted according to the results.
The patients were advised on a regular basis to adhere to a
dietary protein intake of 1.0 g/kg/day with an adequate calorie
intake. The dieticians were not aware of which dialysis fluid/tablet
regime was being used.
Morbidity
Morbidity was assessed in terms of the number of admissions
per year, and days spent in hospital per year. The number of
admissions included only those after the insertion of CAPD
catheter. The days spent in hospital included all admissions for
one year after discharge from the admission that incorporated the
CAPD catheter insertion, any admission(s) immediately before
the CAPD catheter insertion, and the admission for the insertion
of the CAPD catheter.
Outcomes
Seven outcome states were recognized at one year: (1.) CAPD
(whether or not the patient had received a failed transplant, a
temporary period of haemodialysis or intermittent peritoneal
dialysis, or temporary recovery of renal function); (2.) functioning
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Table 2. Nutritional state and laboratory data of the two groups, at baseline (or 1 month) and one year
Nutritional state
Low alkali High alkali
Baseline One year Baseline One year
Weight kg 69.1 1.4 72.8 1.4 68.0 1.3 74.8 1.3
Height cm 167.2 1.0 — 166.5 0.9 —
Midarm circumference cm 28.3 0.4 28.7 0.4 28.2 0.4 29.8 0.4
I month
Triceps skinfold thickness mm 13.6 0.8 14.3 0.8 14.5 0.8 16.1 0.9
1 month
Albumin g/liter 37.2 0.4 38.2 0.5 37.5 0.5 37.8 0.4
Laboratory data
Hemoglobin g/dl 8.9 0.2 11.5 0.2 9.0 0.2 11.2 0.2
Sodium mmol/liter 138.1 0.3 137.2 0.3 137.2 0.3 137.2 0.4
Potassium mmol/liter 4.42 0.09 4.02 0.06 4.62 0.07 4.15 0.06
Urea mmol/liter 40.9 1.6 19.1 0.5 39.7 1.0 19.2 0.5
Creatinine p.rnol/liter 1106 37 888 27 1077 30 852 19
Bicarbonate mmol/liter 20.4 0.6 23 0.3 20.1 0.5 27.2 0.3
Calcium mmol/liter 2.25 0.04 2.51 0.03 2.27 0.03 2.51 0.02
Phosphate mmol/liter
Alkaline phosphatase lU/liter
2.36 0.07
100 4.3
1.87 0.05
103.1 5
2.33 0.07
98 4.9
1.66 0.05"
83.5 2.8k'
PTHpmol/liter - I month 21.2 2.4 15.7 3 23.6 2.5 17 1.9
Cortisol nmol/liter - 1 month 435 7.1 442.5 8.8 431 10.8 544.6 23
Protein catabolic rate g/kg/day 0.88 0.02 0.94 0.03 0.92 0.02 0.89 0.02
1 month
Weekly urea Kt/V - 1 month 1.92 0.06 1.91 0.06 1.89 0.05 1.83 0.05
Weekly creatinine clearance 78.2 3.0 80.1 3.3 76.8 3.3 76.3 2.5
liter/week . 1 month
p < o5, 'p < 0.01, and "P < 0.001
renal transplant; (3.) death; (4.) hemodialysis (HD), where this
was considered the 'permanent' form of renal replacement ther-
apy at that time; (5.) intermittent peritoneal dialysis (IPD), where
this was considered the 'permanent' form of renal replacement
therapy at that time. It took the form of 48 hours of continuous
automated peritoneal dialysis, delivered as an inpatient over the
weekend; (6.) recovered renal function; and (7.) transferred out of
the unit.
The numbers and causes of death and technique failure were
compared in the two groups. Technique failure was defined as
requiring permanent HD or IPD at one year, or where the
decision had been made to convert the patient permanently to
Time, months
Fig. 2. Weight gain (kg) in high () and low (U) alkali groups (5P <
0.05).
HD or IPD before death, transplantation, transfer out or recovery
of renal function.
Analysis
Results were analyzed on an 'intention-to-treat' basis, that is,
patients remained in the group into which they were first random-
ized. Data are presented as means standard error of the mean.
The data and graphs presented include all data from the patients
who had reached that time point. Data after a patient had been
transferred out of the unit was not included in the analysis.
Statistical analysis, using the unpaired Student's t-test, compared
the two groups at one year.
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Fig. 1. Serum venous bicarbonate levels (mmol/liter) in high () and low(•) alkali groups (***P < 0.001).
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Fig. 4. Serum calcium (mmol/liter) in low () and high () alkali
groups.
RESULTS
Matching
The two groups were well matched at baseline, in terms of
epidemiological data, causes of renal failure, nutritional state and
laboratory parameters (Tables I and 2). Table 2 also summarizes
the one year data.
Acid/base balance
To achieve the target serum bicarbonate level of 30 mmol/liter
and target serum calcium of 2.5 mmol/liter, 92 of the HA patients
(at one year or the point of leaving the study) required calcium
carbonate (at an average dose of 2.91 0.16 g per day) as well as
HA dialysate. Thirty-six of the LA patients required calcium
carbonate (0.63 0.11 g per day; P < 0.001). Aluminium
hydroxide was used in 3 of the HA patients compared to 17 of the
LA patients, Alphacalcido! was used in 29 HA patients compared
to 46 LA patients (average dose 0.13 0.02 .tg per day vs. 0.22
0.03 .tg per day; P < 0.05).
Forty-eight of the HA patients (at one year or the point of
leaving the study) also required sodium bicarbonate (at an
average dose of 1.4 0.17 g per day) to achieve the target serum
bicarbonate level. One LA patient required sodium bicarbonate
1 6 12
i . . Parathyroid hormone (pmol/liter) in low () high (E) alkali
groups.
because of symptoms thought to be due to persistent severe
acidosis.
Two LA patients had to be changed to I-IA dialysate because of
persistent hypercalcemia, despite withdrawal of calcium contain-
ing or sustaining agents.
At one year, the arterial pH and venous serum bicarbonate
were 7.44 0.004 and 27.2 0.3 mmol/liter in the HA group, and
23.0 0.3 mmol/liter and 7.4 0.004 in the LA group (both P <
0.001). Serum bicarbonate levels are shown in Figure 1.
There was no difference in systolic or diastolic blood pressure at
one year between the two groups: 130 2/78 1 mm Hg in the
HA group versus 129 3/76 1 mm Hg in the LA group.
Furthermore, there was no difference in the number of antihyper-
tensive drugs used by the two groups at one year.
Nutritional state
At one year, the increase in body weight in the HA group (6.1
(166 kg) was significantly greater than the LA group (3.7] 0.56
kg; Fig. 2; P < 0.05); as was the increase in midarm circumference
(HA patients 1.26 0.16 cm; LA patients 0.61 0.16 cm; Fig. 3;
P < 0.05). The increases in triceps skinfold thickness were not
significantly different (HA 2.5 0.41 mm vs. LA 1.24 0.38 mm).
Serum albumin was not different at one year (Table 2). Dietary
protein intake at one year (HA 0.9 0.2 g/kg/day vs. LA 1.0 0.1
g/kg/day) was not significantly different.
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Table 3. Outcomes at one year
Low alkali High alkali
CAPD 59 69
Transplantation (Tx-working) 16 12
Death 15 12
Hemodialysis 5 5
Intermittent peritoneal dialysis 1 0
Recovery of renal function 3 0
Transferred out 1 2
Total 100 100
Bone metabolism
The target adjusted serum calcium of 2.5 mmol/liter was
achieved by six months in both groups (Fig. 4). At one year, the
calcium was not significantly different in the two groups. Serum
phosphate was lower in the HA patients at one year, when
compared to the LA patients (HA 1.66 mmol/liter vs. LA 1.87
mmol/liter; P < 0.05; Fig. 5). There was no difference in parathy-
roid hormone levels between the two groups at one year (Figure
6). There were two parathyroidectomies in the HA group, com-
pared to none in the LA group.
Dialysis dose
Before one year, there were 17 increases and 6 decreases
dialysis dose in the HA group, compared to 18 and 9 in the LA
group. At one year or at the point of leaving the study, out of the
HA group, 11 patients were using 1.5 liter exchanges, 74 2-liter, 14
2.5-liter and one 3-liter exchanges. In the LA group, 11 patients
were using 1.5 liter exchanges, 71 2-liter, 13 2.5-liter and five
3-liter exchanges. Dialysis dose, at one year or at the point of
leaving the study (HA 8.0 0.1 liters/day vs. LA 8.5 0.3
liters/day) was not significantly different (P = 0.18).
Protein catabolic rates, weekly urea Kt/V and weekly creatinine
clearances were not significantly different at one year in the two
groups (Table 2).
Morbidity
There were fewer hospital admissions in the HA group (1.13
0.16 per patient per year) compared to the LA group (1.71 0.22
per patient per year; P < 0.05). The HA patients spent fewer days
in hospital per year than the LA patients (16.4 1.4 days/year vs.
21.2 1.9 days/year; P < 0.05).
Outcomes
The treatment modality of the two groups at one year is
summarized in Table 3. A similar number of patients were
transplanted in the two groups (15 in the HA group, 17 in the LA
group). Six patients in each group experienced permanent tech-
nique failure. Twelve patients died in the HA group, compared to
15 in the LA group. The causes of technique failure and death are
summarized in Table 4.
DISCUSSION
Preliminary studies have indicated that the control of MA
might have an influence on the long-term nutritional state of
peritoneal dialysis patients. in a two-week prospective uncon-
trolled study of 11 peritoneal dialysis patients, serum bicarbonate
was increased from a mean of 26 mmol/liter to 30 mmol/liter [7].
Table 4. Causes of technique failure and death
Low alkali High alkali
Technique failure
Peritonitis 2 2
Patient unable to cope 2 2
Underdialysis 1 1
Other 1 (1.5 liter bags
too big)
1 (Rectal prolapse!
Tunnel
Total 6
infection)
6
Death
Cardiovascular disease 6 4
Malignancy 5 4
Stopped treatment 2 1
Post-transplantation 1 (infection) 1 (bowel
perforation)
Other 1 (stroke) 2 (1 amyloid, I liver
failure)
Total 15 12
This was associated with a significant reduction in protein cata-
bolic rate, as urea excretion diminished, despite a constant dietary
intake of protein. In a one-year uncontrolled retrospective study,
a much larger group of CAPD patients who had been on dialysis
for over 18 months was investigated [13]. There was a significant
improvement in body weight and midarm circumference when the
serum bicarbonate was increased from a mean of 23.7 to 31.5
mmol/liter. The aim of the present study was to confirm or refute
this effect by means of a large prospective, controlled single-blind
study.
The two groups were well matched at baseline. If anything, the
HA were the 'less well' group at baseline with 22 patients with
diabetes mellitus, compared to 12 in the LA group. The starting
weight of the HA was also slightly lower (68 vs. 69.1 kg).
Even though the different dialysate/medication regimes were
able to produce differences in control of acid-base balance, the
target venous bicarbonate of 30 mmol/liter in the HA group, was
surprisingly difficult to achieve. At one year or at the point of
leaving the study, 92 of the 100 HA patients required calcium
carbonate and/or sodium bicarbonate to achieve the target serum
bicarbonate level.
Despite this, at one year, only 17 out of 69 CAPD patients
(24.6%) who reached that time point had a venous bicarbonate of
30 mmol/liter or over, compared to none in the LA group. Part of
this difficulty can be explained by examining Figure 2. It can be
seen that after three months, there was a progressive decline in
venous bicarbonate in both groups, presumably as a result of the
loss of residual renal function. Furthermore, it appears that the
amount of lactate in HA dialysate (40 mmol/liter), even in
combination with high dose calcium carbonate and/or sodium
bicarbonate, was insufficient to achieve higher bicarbonate levels.
Not surprisingly, it was more difficult to improve acidosis correc-
tion in the larger patients, especially those losing residual renal
function. Also, it is doubtful that when large doses of calcium
carbonate and/or sodium bicarbonate were prescribed, compli-
ance with either drug was optimal.
It is interesting that the effects seen in this study were observed
when neither group was alkalotic or acidotic. Indeed, the effects
on weight gain and midarm circumference observed occurred at
the ends of the normal range of serum venous bicarbonate. In the
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majority of the animal studies carried out so far, in which acidosis
has been shown to increase protein degradation, thc animals were
made profoundly acidotic; for example, in one rat study, art
arterial pH of 7.2 was achieved [141. It is conceivable, however,
whatever the mechanism of this effect, that it is clinically relevant
in patients with end-stage renal failure, within their range of
acid-base balance. As sodium bicarbonate was rcquircd to fully
correct acidosis in many patients in the HA group, it could be
argued that their greater weight gain was secondary to sodium and
water retention. However, if this was the case, one would not
expect blood pressure control to be so similar in the two groups.
Furthermore, there was no significant differencc in the number of
antihypertensive agents by each group. One might also have
expected more hospital admissions in the HA group, due to fluid
overload. In fact, there were less admissions in the HA group.
In terms of nutritional state, this was a very positive study. At
one year, the increase in body weight in the HA group was
significantly higher than in the LA group (6.1 vs. 3.7 kg). When the
2 kg of the weight gain that can be apportioned to the CAPD fluid
in the abdomen is 'removed' from the analysis, the size of this
effect can be appreciated even more. In other words, the 4.1 kg of
true body weight gain in the HA patients is nearly 2.5 times the 1.7
kg weight gain in the LA group. Interestingly, there was no
significant relationship between starting weight and weight gain in
the HA group (r = 0.11; P > 0.35), indicating that the positive
effect seen is apparent over the whole range of patient size, not
just those 'with most to gain,' that is, the malnourished patients.
The increase in midarm circumference at one year in the HA
patients was significantly higher than the increase in the LA
patients (1.26 vs. 0.61 cm), the size of the effect being of similar
proportion to that of the weight gain. The increases in triceps
skinfold thickness (2.5 vs. 1.24 mm), though not statistically
significant, may have been biologically relevant. Comparing the
two groups, the serum albumin was the same throughout the
study, and appeared to slowly rise in both groups during the study.
That lack of difference in serum albumin in the two groups
probably reflects the poor quality of the parameter as a nutritional
marker.
That there was no difference in serum calcium at one year was,
in part, related to the design of the study. A serum adjusted
calcium of 2.5 mmol/liter was one of the target parameters used in
the study, in an attempt to control for variables other than
acid/base balance. Not surprisingly, as five times the dose of
calcium carbonate was prescribed in the HA patients (in an
attempt to make them more alkalotic) the phosphate control was
better in that group. This 'benefit' did not lead to better parathy-
roid hormone control. Indeed, there were two parathyroidecto-
mies in the HA group and none in the LA group.
This study was not designed to investigate the mechanism of
any beneficial effect seen. Nonetheless, some information can he
gained from the data collected, accepting that these data did not
reach statistical significance. Even though the protein catabolic
rates, weekly urea Kt/V and weekly creatinine clearances were not
significantly different at one year, when the direction of change in
values is examined, interesting effects can he seen. All three
parameters (which are proportional to urea or creatinine excre-
tion, and thereby reflect muscle breakdown as well as dialysis
dose) decreased (from 0.92 g/kglday, 1.89 and 76.9 liters per week
at one month to 0.89, 1.85 and 76.3, respectively, at twelve
months) in the HA group, despite an overall tendency to an
increase in dialysis dose over the year. This suggests that there
may have been a decrease in muscle breakdown in the HA
patients over the year of study. Whereas, in the LA group, two out
of three parameters increased (from 0.88 g/kg/day, 1.93 and 78.2
liters per week at one month to 0.94, 1.91 and 80.1 at twelve
months). Indeed, by as early as one month, there was a trend
towards greater kinetic modeling parameters in the LA group
(Table 2). This may indicate that there was an increase in muscle
breakdown in the LA group.
The serum cortisol was significantly higher at one year in the
HA group compared to the LA group (544.6 23 vs. 431 10.8
mmol/liter). This finding is difficult to interpret, as studies carried
out so far, indicate that the increase in protein breakdown
associated with metabolic acidosis is mediated, in part, by an
increase in glucocorticoid secretion [15].
Whatever the mechanism of the effect, it seems likely that a true
metabolic change had occurred, rather than the HA patients
simply ate more, particularly as the dietary protein intake was not
significantly different in the two groups at one year.
In terms of morbidity, the HA patients also fared better than
the LA group as there were significantly less hospital admissions
in the HA group. The HA patients spent, on average, 5 days less
in hospital per year than the LA patients. This apparently small
improvement in hospitalization could have major economic ben-
efits in terms of the cost of CAPD per year, as well as lifestyle
benefits to the patient, if reproduced in large dialysis populations.
The statistical power of this study was never great enough for it to
be a mortality study. It was not designed to show an improvement
in mortality even if a better nutritional state did produce such a
gain. However, it is gratifying that there were 12 deaths in the HA
group compared to 15 in the LA group.
In conclusion, better correction of metabolic acidosis leads to
greater increases in body weight and midarm circumference in
patients on CAPD in the first year of treatment. The improvement
in morbidity observed, in terms of number of admissions and days
in hospital per year, may be associated with the improvement in
nutritional state. It would now seem that the association of
metabolic acidosis and protein metabolism in renal failure, first
documented by Lyon in 1931, has clinical implications in patients
receiving long-term dialysis.
Reprint requests to Professor J. Walls, Department of Nephrology, Leicester
General Hospital NHS Trust, Gwendolen Road, Leicester, LE5 4PW,
England, United Kingdom.
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